Luminus Biosciences

Preclinical Studies

Preclinical Study Results of ABC‑1103

Austin Biosciences has completed several key preclinical studies, including a maximum tolerated dose (MTD) study, a pharmacokinetics study, and biological activities in a breast tumor xenograft model, and in a pancreatic tumor xenograft model.

Results show ABC-1103 vs. Taxotere® has significantly greater anti-tumor activity with potentially reduced toxicity.